ES2811764T3 - Adhesión antileucocitaria para mitigación de posibles eventos adversos causados por dominios de unión específicos de CD3 - Google Patents
Adhesión antileucocitaria para mitigación de posibles eventos adversos causados por dominios de unión específicos de CD3 Download PDFInfo
- Publication number
- ES2811764T3 ES2811764T3 ES14707953T ES14707953T ES2811764T3 ES 2811764 T3 ES2811764 T3 ES 2811764T3 ES 14707953 T ES14707953 T ES 14707953T ES 14707953 T ES14707953 T ES 14707953T ES 2811764 T3 ES2811764 T3 ES 2811764T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- cell
- binding
- adhesion molecule
- endothelial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762718P | 2013-02-08 | 2013-02-08 | |
| US201361811526P | 2013-04-12 | 2013-04-12 | |
| PCT/EP2014/052406 WO2014122251A2 (en) | 2013-02-08 | 2014-02-07 | Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2811764T3 true ES2811764T3 (es) | 2021-03-15 |
Family
ID=50231117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14707953T Active ES2811764T3 (es) | 2013-02-08 | 2014-02-07 | Adhesión antileucocitaria para mitigación de posibles eventos adversos causados por dominios de unión específicos de CD3 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9688760B2 (https=) |
| EP (2) | EP2953630B1 (https=) |
| JP (2) | JP6567425B2 (https=) |
| AR (1) | AR094740A1 (https=) |
| AU (2) | AU2014214020B2 (https=) |
| CA (1) | CA2898032C (https=) |
| ES (1) | ES2811764T3 (https=) |
| JO (1) | JO3529B1 (https=) |
| MX (2) | MX368842B (https=) |
| TW (2) | TW201929865A (https=) |
| UY (1) | UY35313A (https=) |
| WO (1) | WO2014122251A2 (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102345943B1 (ko) * | 2011-04-28 | 2021-12-31 | 암젠 리서치 (뮌헨) 게엠베하 | 잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법 |
| WO2013026839A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| RU2015117393A (ru) | 2012-10-08 | 2016-12-10 | Роше Гликарт Аг | Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения |
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| US9486475B2 (en) * | 2013-02-08 | 2016-11-08 | Amgen Research (Munich) Gmbh | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| LT2961771T (lt) | 2013-02-26 | 2020-03-10 | Roche Glycart Ag | Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams |
| EP2961773B1 (en) | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| US10101247B2 (en) * | 2013-07-19 | 2018-10-16 | Rarecyte, Inc. | Solution and method for adhering suspension components to a substrate |
| IL263466B2 (en) | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| SI3149480T1 (sl) | 2014-05-30 | 2019-05-31 | Amgen Research (Munich) Gmbh | Stratifikacija tveganj pri bolnikih z akutno limfoblastno levkemijo prekurzorjev b |
| EP3177643B1 (en) | 2014-08-04 | 2019-05-08 | F.Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
| MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
| PT3221356T (pt) | 2014-11-20 | 2020-10-29 | Hoffmann La Roche | Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3 |
| EP4141032B1 (en) | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
| DK3221357T3 (da) | 2014-11-20 | 2020-08-10 | Hoffmann La Roche | Fælles letkæder og fremgangsmåder til anvendelse |
| DK3310814T5 (da) | 2015-06-16 | 2024-10-07 | Hoffmann La Roche | Humaniserede og affinitetsmodnede antistoffer mod FcRH5 og fremgangsmåder til anvendelse |
| US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
| EP3340995A4 (en) * | 2015-08-28 | 2019-04-03 | The Trustees Of The University Of Pennsylvania | METHOD AND COMPOSITIONS FOR CELLS FOR EXPRESSING A CHIMERIC INTRA-CELLULAR SIGNAL MOLECULE |
| CN106554414B (zh) * | 2015-09-18 | 2019-04-23 | 上海科济制药有限公司 | 抗cd19全人抗体以及靶向cd19的免疫效应细胞 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| PE20180484A1 (es) | 2015-10-02 | 2018-03-07 | Hoffmann La Roche | Moleculas biespecificas de union a antigeno activadoras de celulas t |
| US10101248B1 (en) * | 2015-12-02 | 2018-10-16 | Rarecyte, Inc. | Solution and method for adhering suspension components to a substrate |
| IL313608A (en) | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| KR20180097615A (ko) | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 |
| JP7015244B2 (ja) | 2016-03-22 | 2022-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化ｔ細胞二重特異性分子 |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| JP6225321B1 (ja) | 2016-08-31 | 2017-11-08 | 王子ホールディングス株式会社 | ポリ硫酸ペントサンの製造方法 |
| EP3677587A4 (en) | 2016-08-31 | 2021-04-14 | Oji Holdings Corporation | XYLOOLIGOSACCHARIDE ACID, AND METHOD FOR MANUFACTURING THE SAME |
| US10882918B2 (en) | 2016-09-30 | 2021-01-05 | Hoffmann-La Roche Inc. | Bispecific T cell activating antigen binding molecules |
| JP7784795B2 (ja) | 2016-11-15 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| JP6281659B1 (ja) | 2017-02-28 | 2018-02-21 | 王子ホールディングス株式会社 | ポリ硫酸ペントサン、医薬組成物及び抗凝固剤 |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| EP3612210A4 (en) | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS |
| CA3065747C (en) | 2017-05-31 | 2024-10-01 | Oji Holdings Corporation | MOISTURIZING COMPOSITION CONTAINING PENTOSANNE POLYSULFATE |
| PL3683242T3 (pl) | 2017-09-12 | 2025-03-03 | Oji Holdings Corporation | Polisiarczan pentozanu i sposób wytwarzania polisiarczanu pentozanu |
| KR20260026092A (ko) | 2017-09-19 | 2026-02-25 | 메사추세츠 인스티튜트 오브 테크놀로지 | 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도 |
| KR102533822B1 (ko) | 2017-12-20 | 2023-05-17 | 오지 홀딩스 가부시키가이샤 | 폴리황산펜토산 및 폴리황산펜토산을 포함하는 의약 |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| US12312416B2 (en) | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| IL325995A (en) | 2018-02-08 | 2026-03-01 | Genentech Inc | Bispecific antigen binding molecules and methods of use |
| US12473336B2 (en) | 2018-02-21 | 2025-11-18 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| AU2019346335B2 (en) | 2018-09-28 | 2024-07-25 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| WO2020221792A1 (en) * | 2019-04-30 | 2020-11-05 | Amgen Research (Munich) Gmbh | Means and methods of treating burkitt lymphoma or leukemia |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2020263399A1 (en) | 2019-06-26 | 2020-12-30 | Massachusetts Institute Of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| CN115210252A (zh) | 2020-02-04 | 2022-10-18 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗二硝基苯酚的嵌合抗原受体 |
| BR112022017924A2 (pt) | 2020-03-10 | 2022-12-20 | Massachusetts Inst Technology | Composições e métodos para imunoterapia de câncer npm1c-positivo |
| JP2023517063A (ja) | 2020-03-10 | 2023-04-21 | マサチューセッツ インスティテュート オブ テクノロジー | 操作されたメモリー様ｎｋ細胞を作製するための方法およびその組成物 |
| WO2021179047A1 (en) * | 2020-03-12 | 2021-09-16 | Cullis Hill Sydney David | Treatment for coronavirus infection and associated cytokine toxicity |
| US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| US12433954B2 (en) | 2020-05-01 | 2025-10-07 | Massachusetts Institute Of Technology | Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| WO2021255155A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cd19 |
| MX2023003041A (es) * | 2020-09-16 | 2023-05-09 | Amgen Inc | Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer. |
| AU2021374594B2 (en) | 2020-11-04 | 2026-03-05 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| TWI874719B (zh) | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
| JP7716473B2 (ja) | 2020-11-04 | 2025-07-31 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 |
| CN112521513B (zh) * | 2020-12-15 | 2021-08-24 | 青岛西凯生物技术有限公司 | 一种靶向cd19的嵌合抗原受体(car)及其应用 |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| EP4337330A1 (en) | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| CN113637087A (zh) * | 2021-07-09 | 2021-11-12 | 上海易慕峰生物科技有限公司 | 一种提高细胞免疫疗法安全性的嵌合受体和细胞 |
| US20260083848A1 (en) | 2021-11-03 | 2026-03-26 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| WO2024206166A1 (en) * | 2023-03-31 | 2024-10-03 | Memorial Sloan-Kettering Cancer Center | Microenvironment actuated t-cells and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2689848A (en) | 1951-02-06 | 1954-09-21 | Wander Ag Dr A | Salts of sulfuric acid esters of xylan |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5605938A (en) * | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| AU687755B2 (en) | 1992-08-21 | 1998-03-05 | Genentech Inc. | Method for treating an LFA-1-mediated disorder |
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| JP2008501621A (ja) | 2003-05-31 | 2008-01-24 | マイクロメット アクツィエン ゲゼルシャフト | Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物 |
| CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| HRP20150175T1 (en) | 2005-12-16 | 2015-03-27 | Amgen Research (Munich) Gmbh | Means and methods for the treatment of tumorous diseases |
| CA2651174A1 (en) | 2006-05-03 | 2007-11-15 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| SG177907A1 (en) * | 2006-06-14 | 2012-02-28 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| WO2008107906A1 (en) | 2007-03-06 | 2008-09-12 | Alembic Limited | Process for the preparation of pentosan polysulfate or salts thereof |
| RS53008B2 (sr) * | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| MX2009010611A (es) | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
| RU2769948C2 (ru) | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| TW200914048A (en) * | 2007-07-17 | 2009-04-01 | Combinatorx Inc | Combinations for the treatment of B-cell proliferative disorders |
| AU2008276451A1 (en) * | 2007-07-17 | 2009-01-22 | Zalicus Inc. | Treatments of B-cell proliferative disorders |
| EP2188281A1 (en) | 2007-08-10 | 2010-05-26 | Y's Therapeutics Co, Ltd. | Modulation of immune responses by administration of roxithromycin or its derivative |
| US8026343B2 (en) | 2008-08-08 | 2011-09-27 | Dinona Inc. | Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof |
| US20110293619A1 (en) * | 2008-10-01 | 2011-12-01 | Micromet Ag | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY |
| RS54655B2 (sr) * | 2009-10-27 | 2021-04-29 | Amgen Res Munich Gmbh | Dozni režim za primenu cd19xcd3 bispecifičnog antitela |
| CN103459425B (zh) * | 2010-10-27 | 2015-11-25 | 安进研发（慕尼黑）股份有限公司 | 用于治疗dlbcl的组合物 |
| EA026075B1 (ru) * | 2010-11-10 | 2017-02-28 | Эмджен Рисерч (Мьюник) Гмбх | Предотвращение неблагоприятных эффектов, вызванных cd3-специфическими связывающими доменами |
| KR20140004174A (ko) * | 2011-01-18 | 2014-01-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 치료를 위한 조성물 및 방법 |
| KR102345943B1 (ko) * | 2011-04-28 | 2021-12-31 | 암젠 리서치 (뮌헨) 게엠베하 | 잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법 |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| CN102875685B (zh) | 2012-09-29 | 2013-12-25 | 郑骏年 | 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途 |
| US9486475B2 (en) * | 2013-02-08 | 2016-11-08 | Amgen Research (Munich) Gmbh | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
-
2014
- 2014-02-06 JO JOP/2014/0028A patent/JO3529B1/ar active
- 2014-02-07 AR ARP140100416A patent/AR094740A1/es unknown
- 2014-02-07 EP EP14707953.7A patent/EP2953630B1/en active Active
- 2014-02-07 MX MX2015009922A patent/MX368842B/es active IP Right Grant
- 2014-02-07 JP JP2015556506A patent/JP6567425B2/ja active Active
- 2014-02-07 EP EP20182831.6A patent/EP3760210A1/en not_active Withdrawn
- 2014-02-07 AU AU2014214020A patent/AU2014214020B2/en active Active
- 2014-02-07 TW TW107140068A patent/TW201929865A/zh unknown
- 2014-02-07 ES ES14707953T patent/ES2811764T3/es active Active
- 2014-02-07 CA CA2898032A patent/CA2898032C/en active Active
- 2014-02-07 TW TW103104162A patent/TWI704920B/zh active
- 2014-02-07 MX MX2019012421A patent/MX2019012421A/es unknown
- 2014-02-07 WO PCT/EP2014/052406 patent/WO2014122251A2/en not_active Ceased
- 2014-02-07 UY UY0001035313A patent/UY35313A/es unknown
- 2014-02-08 US US14/176,091 patent/US9688760B2/en active Active
-
2017
- 2017-05-24 US US15/604,341 patent/US11084876B2/en active Active
-
2019
- 2019-02-07 AU AU2019200841A patent/AU2019200841B2/en active Active
- 2019-05-28 JP JP2019098999A patent/JP6933684B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170327581A1 (en) | 2017-11-16 |
| AU2019200841B2 (en) | 2020-08-13 |
| MX2015009922A (es) | 2015-09-25 |
| UY35313A (es) | 2014-08-29 |
| US20140227272A1 (en) | 2014-08-14 |
| JP2019178142A (ja) | 2019-10-17 |
| JP6567425B2 (ja) | 2019-08-28 |
| CA2898032C (en) | 2021-06-15 |
| JO3529B1 (ar) | 2020-07-05 |
| AU2014214020A1 (en) | 2015-07-30 |
| WO2014122251A3 (en) | 2014-10-02 |
| JP6933684B2 (ja) | 2021-09-08 |
| EP2953630A2 (en) | 2015-12-16 |
| MX368842B (es) | 2019-10-18 |
| US11084876B2 (en) | 2021-08-10 |
| TWI704920B (zh) | 2020-09-21 |
| US9688760B2 (en) | 2017-06-27 |
| TW201442714A (zh) | 2014-11-16 |
| AR094740A1 (es) | 2015-08-26 |
| EP2953630B1 (en) | 2020-07-01 |
| WO2014122251A2 (en) | 2014-08-14 |
| TW201929865A (zh) | 2019-08-01 |
| EP3760210A1 (en) | 2021-01-06 |
| AU2019200841A1 (en) | 2019-02-28 |
| JP2016514090A (ja) | 2016-05-19 |
| MX2019012421A (es) | 2022-10-13 |
| CA2898032A1 (en) | 2014-08-14 |
| AU2014214020B2 (en) | 2018-11-15 |
| HK1216996A1 (zh) | 2016-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2811764T3 (es) | Adhesión antileucocitaria para mitigación de posibles eventos adversos causados por dominios de unión específicos de CD3 | |
| US12227575B2 (en) | Combination of TIM-4 antagonist and PD-1 antagonist and methods of use | |
| JP2019517773A (ja) | 抗ｌａｇ−３抗体 | |
| JP2019513400A (ja) | エクスビボのｂｉｔｅ活性化ｔ細胞 | |
| US20230125234A1 (en) | Anti cd44-ctla4 bispecific antibodies | |
| CN111655286A (zh) | 作为免疫调节剂的cd96结合剂 | |
| Markmann et al. | On the road to eliminating long‐lived plasma cells—“are we there yet?” | |
| WO2022256723A2 (en) | Tgf-beta inhibitors and therapeutic use thereof | |
| Bakacs et al. | Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy) | |
| US20240409653A1 (en) | Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers | |
| CA2948771C (en) | Risk-stratification of b-precursor acute lymphoblastic leukemia patients | |
| US20240294623A1 (en) | Tgf-beta inhibitors and therapeutic use thereof | |
| ES2975410T3 (es) | Anticuerpos biespecíficos que se unen a HVEM y CD9 | |
| CN118742323A (zh) | Kir3dl3抑制剂和免疫细胞激活剂 | |
| Keats et al. | Daratumumab induces CD38 internalization and impairs myeloma cell adhesion |